Market capitalization | $4.91m |
Enterprise Value | $4.38m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-12.40m |
Free Cash Flow (TTM) Free Cash Flow | $-9.51m |
Cash position | $560.00k |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Bio-Path Holdings, Inc.:
1 Analyst has issued a forecast Bio-Path Holdings, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.15 -0.15 |
17%
17%
|
|
EBITDA | -12 -12 |
26%
26%
|
EBIT (Operating Income) EBIT | -12 -12 |
26%
26%
|
Net Profit | -11 -11 |
37%
37%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the develpment of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline include Prexigebersen, BP1002, and BP1003. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
Head office | United States |
CEO | Peter Nielsen |
Employees | 10 |
Founded | 2007 |
Website | www.biopathholdings.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.